Hedyeh Ebrahimi, MD, MPH, discusses updated data from a phase 1 study of CBM588, cabozantinib, and nivolumab in metastatic renal cell carcinoma.
Hedyeh Ebrahimi, MD, MPH
Advertisement
Hedyeh Ebrahimi, MD, MPH, is a postdoctoral fellow at City of Hope Comprehensive Cancer Center in Duarte, CA.
Articles by Hedyeh Ebrahimi, MD, MPH
Hedyeh Ebrahimi, MD, MPH, discusses a study that found adding the live bacterial product CBM588 to standard immunotherapy potentially impacted patients' responses in renal cell carcinoma.
Advertisement
Latest Updated Articles
The Gut Microbiome and Immunotherapy: New Research Explores CBM588's Mechanism in mRCCPublished: February 25th 2024 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
